Alliance Study Finds Adding Atezolizumab to Standard Chemotherapy Lowers Risk of Cancer Coming Back in Patients with Stage III Colon Cancer

The Alliance for Clinical Trials in Oncology announced results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstr

• Read more